Mr. Swirsky is President and Chief Executive Officer of publicly traded Rexahn Pharmaceuticals, Inc. In addition to his roles at Rexahn, Mr. Swirsky is currently Chairman of the Board of Cellectar Biosciences, Inc., a publicly traded, clinical stage biopharmaceutical company. He has more than two decades of relevant experience in the biopharmaceutical and healthcare sectors, having served as a director of, or in senior management positions at, a number of publicly held companies over the last 14 years and having provided counsel to corporate clients as a healthcare investment banker. Prior to joining Rexahn in January 2018, from 2013 through its sale to Precigen, Inc. (formerly known as Intrexon Corporation) in 2017, Mr. Swirsky was President and Chief Executive Officer of publicly traded biotechnology company, GenVec, Inc., which he joined in 2006 as Chief Financial Officer. Prior to joining GenVec, Mr. Swirsky worked at Stifel Nicolaus, where he served as a managing director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason.
Mr. Swirsky is a certified public accountant and a CFA® charterholder. He earned a B.S. in Business Administration from Boston University and an M.B.A. from the Kellogg School of Management at Northwestern University.
Mr. Kim is General Counsel and a Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs, positions he has held since April 2018. He previously served as Executive Director of Dong-A Socio Holdings Co., Ltd. from January 2016 through March 2018. Earlier, from January 2012 to March 2018, Mr. Kim was Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., the holding company for the Dong-A Socio Group of companies. Prior to joining Dong-A Socio Group, from March 2008 to December 2011, Mr. Kim served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. Since April 2021, Mr. Kim has served as a director of both AnaPath Services GmbH, a private Swiss-based provider of scientific research and development services, and STP America Research Corp, a private New Jersey-based research and development company.
Mr. Kim received his Bachelor of Law degree from Soongshil University in Korea and his Juris Doctor from Washington University School of Law.
Mr. Koven has served as a member of the board of directors of Kala Pharmaceuticals, Inc. since September 2017 and as Lead Independent Director since December 2018. He was, until his retirement in January 2019, the President and Chief Business Officer of Aralez Pharmaceuticals Inc., and served in that role with the company’s predecessor, Pozen Inc., commencing in June 2015. Prior to joining Pozen, Mr. Koven was Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc. from February 2012 until January 2015, when it was acquired by Endo International plc. Before that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc. from July 2010 until May 2011, when it was acquired by Merck & Co., Inc. Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. from March 2007 until February 2010, when it was acquired by Dainippon Sumitomo Pharma Co., Ltd.(now Sunovion.) Prior to that, he was Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc. from August 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in New York, and from 1992 to 1993, he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S.
Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhousie University.
Mr. Groves has served as Executive Vice President and General Counsel of Medifast, Inc. since November 2011, and as the company’s Corporate Secretary since June 2015. Mr. Groves was a director of the company from 2009 to 2015. He served as an independent director and member of the Audit Committee from 2009 to 2011 and on the Executive Committee from 2011 to 2015. Prior to joining Medifast, from 2003 to 2011, Mr. Groves was Assistant Vice President of Government Affairs for Verizon Maryland, which he joined as a Senior Staff Consultant in 2001. Mr. Groves is a United States Army veteran. He was a direct commissioned Judge Advocate in the United States Army Judge Advocate General’s (JAG) Corp. As a JAG Officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant United States Attorney. Over the course of three years, he received two Army Achievement Medals, and one Army Commendation Medal.
Mr. Groves is a member of the New Jersey and District of Columbia bars, as well as several bar associations.
Mr. Salsbury is an attorney with nearly 30 years of experience as a senior executive with public and private companies and in private law practice. Since September 2017, Mr. Salsbury has served as Counsel to Verisma Systems, Inc., a provider of cloud-based automated disclosure management systems. From February 2013 to July 2017, he was Secretary and General Counsel to Best Doctors, Inc., a provider of expert medical opinions.
Mr. Salsbury earned a B.A from Dartmouth College and J.D and M.B.A. degrees from the University of Virginia.
Ms. Kim is the Chief Executive Officer of E&Investment, Inc., a South Korean venture capital firm specializing in investments in life sciences companies, a position she has held since March 2018. From October 2015 until March 2018, Ms. Kim was a Representative Director for The SEED Investment Co., Ltd. (formerly known as OST Investment Co., Ltd.), a South Korean investment and fund manager specializing in investments in life sciences companies. From January 2015 until December 2017, Ms. Kim served as member of the board of directors of Macrogen, Inc., a South Korean, publicly-traded biotechnology company specializing in precision medicine and biotechnology. Ms. Kim focuses on investment opportunities in several industries, particularly in the field of biopharmaceuticals, and has more than 15 years of experience investing in private equity/venture capital markets. As an investor representative, Ms. Kim has successfully managed more than $400 million in private equity and venture capital funds.
Ms. Kim earned an M.S. and B.S. in biomolecular engineering, as well as an M.B.A. from Yonsei University in Korea.
Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc.
Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. in Plant Molecular Genetics from Seoul National University, and a B.S. in Horticultural Science from Seoul National University.